BioSpace News Archive

LG Chem recently announced that the Company has submitted an IND application to the US FDA for its first independent global Phase 3 clinical trial of its new gout drug ‘Tigulixostat’ (clinical program name: EURELIA_1 Study).

According to Vision Research Reports, the global topical drugs market was valued at USD 97.51 billion in 2021 and it is predicted to surpass around USD 217.9 billion by 2030 with a CAGR of 9.35% from 2022 to 2030.

According to Vision Research Reports, the U.S. in vitro diagnostics market was valued at USD 55.3 billion in 2021 and it is predicted to surpass around USD 36.7 billion by 2030 with a CAGR of -4.45% from 2022 to 2030.

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today presented data showing the use of novel antibodies targeting hyperphosphorylated forms of tau.

According to the most recent estimate by Emergen Research, the worldwide 3D ultrasound market will be worth USD 3.28 billion in 2021 and will experience a revenue CAGR of 6.5% over the projected period.

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Acebutolol Hydrochloride Capsules.

Merck, known as MSD outside the United States and Canada, announced that the Phase 3 KEYNOTE-921 trial evaluating KEYTRUDA in combination with chemotherapy compared to chemotherapy alone did not meet its dual primary endpoints of overall survival and radiographic progression-free survival for the treatment of patients with metastatic castration-resistant prostate cancer.

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce it has been invited to present the results from its Phase 2a Study of NP-120 (“Ifenprodil”) for idiopathic pulmonary fibrosis (“IPF”) and Chronic Cough, at the 9th American Cough Conference in June, 2023.

ZyVersa Therapeutics, Inc., (ZyVersa) a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, and Larkspur Health Acquisition Corp. (NASDAQ: LSPR or “Larkspur”), a blank-check special purpose acquisition company are pleased to announce that Translational Research has published data highlighting the differentiated mechanism of action of ZyVersa’s Inflammasome ASC Inhibitor, IC 100.

Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, announced today that it will report second quarter 2022 earnings results for the period ended July 1, 2022, on Thursday, August. 11, 2022.